16.28
0.68%
0.11
Myriad Genetics Inc Stock (MYGN) Financials Data
Income Statement
Quarterly
*All numbers in millions
Period End Date | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Period Length | 3 Months | 3 Months | 3 Months | 3 Months | 3 Months |
Revenues |
2.85%
202.20
|
196.60 | 191.90 | 183.50 | 181.20 |
Cost Of Revenue |
64.60
|
- | 57.60 | 57.80 | 59.20 |
Gross Profit |
137.60
|
- | 134.30 | 125.70 | 122.00 |
Operating Expenses
|
58.89%
165.50
|
402.60 | 194.40 | 239.40 | 174.20 |
Interest Income/Expense |
44.44%
0.50
|
0.90 | 1.00 | 0.50 | 0.50 |
Benefits Costs and Expenses |
0.35%
228.10
|
228.90 | 253.10 | 299.60 | 233.80 |
Costs And Expenses |
0.92%
230.10
|
228.00 | 252.00 | 297.20 | 233.40 |
Depreciation and Amortization |
3.97%
15.70
|
15.10 | 14.10 | 13.30 | 19.40 |
Operating Income/Loss |
11.15%
-27.90
|
-31.40 | -60.10 | -113.70 | -52.20 |
Nonoperating Income/Loss |
322.22%
2.00
|
-0.90 | -1.10 | -2.40 | -0.40 |
Income/Loss From Continuing Operations Before Tax |
19.81%
-25.90
|
-32.30 | -61.20 | -116.10 | -52.60 |
Income Tax Expense/Benefit |
109.09%
0.10
|
-1.10 | 0.10 | - | 2.10 |
Income/Loss From Continuing Operations After Tax |
16.67%
-26.00
|
-31.20 | -61.30 | -116.10 | -54.70 |
Net Income/Loss
|
16.67%
-26.00
|
-31.20 | -61.30 | -116.10 | -54.70 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
7,392%
89.90
|
1.20 | 81.90 | 81.70 | 81.30 |
Diluted Average Shares |
7,392%
89.90
|
1.20 | 81.90 | 81.70 | 81.30 |
Basic Earnings Per Share |
14.71%
-0.29
|
-0.34 | -0.75 | -1.42 | -0.67 |
Diluted Earnings Per Share |
14.71%
-0.29
|
-0.34 | -0.75 | -1.42 | -0.67 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):